Clinical Trial Update: Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 study of AZD0328 in schizophrenia was terminated, with results posted, evaluating pharmacodynamics, pharmacokinetics, safety and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• AZD0328

Snippet

Sponsor: AstraZeneca | Conditions: Schizophrenia | Phase 2 | Status: TERMINATED | Results posted: 2010-08-06